AII
ALNY icon

AGF Investments Inc’s Alnylam Pharmaceuticals ALNY Stock Holding History

AGF Investments Inc’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-2,882
Closed -$489K – 437
2021
Q4 		$489K Sell
2,882
-529
-16% -$98.3K ﹤0.01% 482
2021
Q3 		$644K Buy
3,411
+260
+8% +$48.8K ﹤0.01% 459
2021
Q2 		$534K Buy
3,151
+2,035
+182% +$298K ﹤0.01% 479
2021
Q1 		$158K Sell
1,116
-441
-28% -$66.4K ﹤0.01% 670
2020
Q4 		$202K Sell
1,557
-3,670
-70% -$490K ﹤0.01% 588
2020
Q3 		$761K Buy
5,227
+2,921
+127% +$415K 0.01% 396
2020
Q2 		$342K Buy
2,306
+2,298
+28,725% +$310K ﹤0.01% 476
2020
Q1 		$1K Buy
+8
New +$923 ﹤0.01% 779

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AGF Investments Inc's ALNY Position: Q1 2022 in Review

AGF Investments Inc sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2022, closing a stake of 2,882 shares — an estimated $489K sold.

AGF Investments Inc first reported a position in ALNY in Q1 2020 and held it in 8 quarters. The position peaked at $761K in Q3 2020. 444 funds tracked by Wall St. Rank hold ALNY as of Q1 2022.

  • AGF Investments Inc reported no remaining Alnylam Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • AGF Investments Inc sold 2,882 Alnylam Pharmaceuticals shares in Q1 2022, an estimated $489K.
  • AGF Investments Inc first reported a position in Alnylam Pharmaceuticals in Q1 2020 and held it in 8 quarters.
  • AGF Investments Inc's Alnylam Pharmaceuticals position peaked at $761K in Q3 2020.
  • 444 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2022.

Based on AGF Investments Inc's 13F filing for Q1 2022, filed 10 May 2022.